SYS ONLINE
SUPPLEMENT_SCHOLAR
evidence · mechanism · dose
Experimental/Healing & RepairResearch peptide

Thymosin Beta-4

aka TB-4

Full-length actin-sequestering peptide central to wound healing and angiogenesis — TB-500 is its derivative.

Educational explainer of a research peptide. Profiles in this section deliberately omit clinical-trial citations, dosing protocols, and purchase links. Not FDA-approved as a supplement; not a recommendation to use.

Overview

Thymosin Beta-4 is a 43-amino-acid actin-sequestering peptide present throughout the body that supports tissue repair, angiogenesis, and immune modulation.

Source
  • Endogenously produced; synthesized for research
Forms
  • Subcutaneous injection
  • Eye drops (clinical trials)

Mechanism of action

Sequesters G-actin to control cytoskeletal dynamics for cell migration; also upregulates VEGF and matrix-remodeling enzymes.

Pathways
  • · G-actin sequestration
  • · VEGF and angiogenesis
  • · MMP-driven matrix remodeling
Enzymes
  • · MMPs (modulated)

How it acts on the body

Thymosin Beta-4 is one of the most abundant intracellular peptides in mammals. By binding monomeric G-actin, it acts as a reservoir that controls how quickly cells can polymerize new actin filaments — a prerequisite for cell migration, which is itself a prerequisite for closing wounds and angiogenesis.

Beyond actin handling, it upregulates VEGF and matrix metalloproteinases, supports endothelial-cell tube formation, and shifts immune signaling toward repair rather than inflammation. TB-500 is a fragment of this molecule used as a research surrogate.

Hormonal & endocrine impact

How this peptide is reported to shift specific hormones and signaling molecules. Directionality reflects research literature and preclinical models, not clinical prescribing data.

Projected hormonal trajectory
Illustrative curves derived from reported direction of effect. Not measured patient data.

Curves are schematic shapes (sigmoid for increases/decreases, damped oscillation for modulation/stabilization) anchored to a 100% baseline. They communicate direction and tempo of change reported in research literature — not absolute hormone concentrations.

VEGFIncreases
Pro-angiogenic signaling at sites of repair.
Inflammatory cytokinesDecreases
Shifts toward resolution-phase signaling.
MMP activityModulates
Coordinated matrix remodeling rather than indiscriminate breakdown.

Effects on the body

Supports
Wound healing and angiogenesis
Decreases
Excess inflammation
Supports
Cell migration during repair

Organ system effects

Cardiovascular

Cardiac-repair signaling in animal models.

Eye

Trials in dry-eye and corneal-healing settings.

Skin

Pro-healing effects across multiple wound models.

Immune System

Resolution-phase immune signaling.

Reported effects

Drawn from preclinical research, anecdote, and small-scale clinical observation. No evidence grades are assigned — most peptides on this page lack rigorous human trials.

  • Broad tissue-repair signaling
  • Active clinical trials in eye and cardiovascular medicine

Potential side effects

Common
  • · Injection-site reactions
  • · Mild fatigue
Rare
  • · Headache
Serious
  • · Long-term human safety not fully characterized

Drug interactions

No notable interactions reported.

Pairing context

Often combined with
  • BPC-157
    Complementary angiogenesis and migration support.
Avoid combining with
  • Active malignancy
    VEGF upregulation is generally avoided.
Important. Research peptides described here are not FDA-approved supplements. Supplement Scholar does not endorse, recommend, or link to any source for purchase. Consult a qualified clinician before considering any peptide therapy.